Bahram Valamehr - Jul 7, 2022 Form 4 Insider Report for FATE THERAPEUTICS INC (FATE)

Role
Chief R&D Officer
Signature
/s/ Cindy Tahl, as Attorney-in-Fact
Stock symbol
FATE
Transactions as of
Jul 7, 2022
Transactions value $
-$518,686
Form type
4
Date filed
7/8/2022, 04:51 PM
Previous filing
Jul 7, 2022
Next filing
Jan 11, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction FATE Common Stock Options Exercise $46.8K +17.2K +9.54% $2.73 197K Jul 7, 2022 Direct F1
transaction FATE Common Stock Sale -$519K -17.2K -8.71% $30.23* 180K Jul 7, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FATE Stock Option (Right to Buy) Options Exercise -$46.8K -17.2K -56.6% $2.73 13.2K Jul 7, 2022 Common Stock 17.2K $2.73 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 9, 2020.
F2 Represents the weighted average sale price of the shares sold ranging from $30.00 to $30.53 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each price within the range set forth in footnote 2.
F3 This option is fully vested.